Specialty code 1835P2201X · Wilmington, NC
NPI
1356946420
Since 2020
Specialty
Specialty code 1835P2201X
Code 1835P2201X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
2250 Shipyard Blvd Ste 12
Wilmington, NC, 28403
Phone (910) 662-7757
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$1.4M
885 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Geena D Eglin prescribed most often to Medicare patients was Repatha Sureclick (Evolocumab), with 133 prescriptions and refills. In total Geena D Eglin wrote 885 Medicare prescriptions that cost $1.4M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-19.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Repatha Sureclick Evolocumab | 133 | 312 | 48 | $171K |
| Nexletol Bempedoic Acid | 78 | 170 | 19 | $66K |
| Forteo Teriparatide | 67 | 73 | Under 11 | $289K |
| Praluent Pen Alirocumab | 52 | 112 | 19 | $54K |
| Ezetimibe Generic | 49 | 115 | 20 | $758 |
| Evenity (2 Syringes) Romosozumab-Aqqg | 45 | 45 | Under 11 | $102K |
| Orencia Clickject Abatacept | 40 | 40 | Under 11 | $209K |
| Vascepa Icosapent Ethyl | 40 | 79 | Under 11 | $26K |
| Tymlos Abaloparatide | 37 | 37 | Under 11 | $91K |
| Prolia Denosumab | 34 | 201 | 30 | $56K |
| Otezla Apremilast | 24 | 24 | Under 11 | $107K |
| Methotrexate Methotrexate Sodium | 17 | 22 | Under 11 | $116 |
| Rasuvo Methotrexate/Pf | 17 | 19 | Under 11 | $9,735 |
| Trueplus Pen Needle Pen Needle, Diabetic | 16 | 49 | Under 11 | $740 |
| Leqvio Inclisiran Sodium | 14 | 44 | Under 11 | $45K |
Brand drugs: 702 claims; generic drugs: 160 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Geena D Eglin were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.